[A view of development of new antibacterial agents with novel targets].
Watanabe
Yasuo
Y
Clinical Research Department, Toyama Chemical Co., Ltd.
Minami
Shinzaburo
S
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors; D000581:Amidohydrolases / Q000037:antagonists & inhibitors; D000626:Aminopeptidases / Q000037:antagonists & inhibitors; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001419:Bacteria / Q000166:cytology / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D001426:Bacterial Proteins / Q000096:biosynthesis; D002473:Cell Wall / Q000378:metabolism; D004269:DNA, Bacterial / Q000096:biosynthesis; D003864:Depression, Chemical; D015195:Drug Design; D024881:Drug Resistance, Bacterial; D050753:Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); D005227:Fatty Acids / Q000096:biosynthesis; D006801:Humans; D010088:Oxidoreductases / Q000037:antagonists & inhibitors
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D005227:Fatty Acids; D010088:Oxidoreductases; D050753:Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); D019883:Alkyl and Aryl Transferases; C022566:UDP-N-acetylglucosamine 1-carboxyvinyltransferase; D000626:Aminopeptidases; D000581:Amidohydrolases; C097307:UDP-3-O-acyl-N-acetylglucosamine deacetylase; C084507:peptide deformylase